FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Katharine Whartenby

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Physiology

Procedures

Genetic Therapy

Disorders

Co-author Network

Publications

TOP 3
Lina Hu; Joseph B Margolick; Avindra Nath; TONGGUANG WANG; Katharine A Whartenby; Hao Zhang; Anne R Gocke; Peter A Calabresi
Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes.
Anne R Gocke; Inna V Grishkan; Lina Hu; Lori A Lebson; Hai M Nguyen; Katharine A Whartenby; K George Chandy; Peter A Calabresi
Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.
Lina Hu; Emily G Baxi; Katharine A Whartenby; Edward Knapp; Jason M Rosenzweig; Hao Zhang; Joseph B Margolick; Inna V Grishkan; Anne R Gocke; Peter A Calabresi
Functional blockade of the voltage-gated potassium channel Kv1.3 mediates reversion of T effector to central memory lymphocytes through SMAD3/p21cip1 signaling.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Katharine Whartenby (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Lina Hu; Joseph B Margolick; Avindra Nath; TONGGUANG WANG; Katharine A Whartenby; Hao Zhang; Anne R Gocke; Peter A Calabresi
Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B secretion of human CD8+ T effector memory lymphocytes.
PloS one 2013;8(1):e54267.
2012: Anne R Gocke; Inna V Grishkan; Lina Hu; Lori A Lebson; Hai M Nguyen; Katharine A Whartenby; K George Chandy; Peter A Calabresi
Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis.
Journal of immunology (Baltimore, Md. : 1950) 2012;188(12):5877-86.
2012: Lina Hu; Emily G Baxi; Katharine A Whartenby; Edward Knapp; Jason M Rosenzweig; Hao Zhang; Joseph B Margolick; Inna V Grishkan; Anne R Gocke; Peter A Calabresi
Functional blockade of the voltage-gated potassium channel Kv1.3 mediates reversion of T effector to central memory lymphocytes through SMAD3/p21cip1 signaling.
The Journal of biological chemistry 2012;287(2):1261-8.
2011: L Lebson; Tianhong Wang; Q Jiang; Katharine A Whartenby
Induction of the glucocorticoid-induced leucine zipper gene limits the efficacy of dendritic cell vaccines.
Cancer gene therapy 2011;18(8):563-70.
2011: Mario Skarica; Katharine A Whartenby; Christopher Eckstein; Peter A Calabresi
Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients.
Journal of neuroimmunology 2011;235(1-2):70-6.
2010: Lori Lebson; Anne E. Gocke; Jason Rosenzweig; Jonathan Alder; Curt I Civin; Peter A Calabresi; Katharine A Whartenby
Cutting edge: The transcription factor Kruppel-like factor 4 regulates the differentiation of Th17 cells independently of RORγt.
Journal of immunology (Baltimore, Md. : 1950) 2010;185(12):7161-4.
2010: Cynthia A DeBoy; Horea Rus; Cosmin Tegla; Cornelia Cudrici; Melina Jones; CARLOS PARDO-VILLAMIZAR; Donald Small; Katharine A Whartenby; Peter A Calabresi
FLT-3 expression and function on microglia in multiple sclerosis.
Experimental and molecular pathology 2010;89(2):109-16.
2009: Mario Skarica; Tianhong Wang; Erin McCadden; David Kardian; Peter A Calabresi; Donald Small; Katharine A Whartenby
Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(7):4192-9.
2009: Tianhong Wang; Qiong Jiang; Camie W Y Chan; Kevin Gorski; Erin McCadden; David Kardian; Drew M Pardoll; Katharine A Whartenby
Inhibition of activation-induced death of dendritic cells and enhancement of vaccine efficacy via blockade of MINOR.
Blood 2009;113(13):2906-13.
2008: Katharine A Whartenby; Donald Small; Peter A Calabresi
FLT3 inhibitors for the treatment of autoimmune disease.
Expert opinion on investigational drugs 2008;17(11):1685-92.
2008: Melina Jones; THIEN NGUYEN; C A Deboy; John W Griffin; Katharine A Whartenby; Douglas A Kerr; Peter A Calabresi
Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis.
Journal of neuroimmunology 2008;199(1-2):83-93.
2008: Guo N Huang; David L Huso; Samuel Bouyain; Jianchen Tu; Kelly A McCorkell; Michael May; Yuwen Zhu; Michael Lutz; Samuel Collins; Marlin H Dehoff; Shin Kang; Katharine A Whartenby; Jonathan D Powell; Daniel J Leahy; Paul F Worley
NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins.
Science (New York, N.Y.) 2008;319(5862):476-81.
2007: Lina Hu; Michael Pennington; Qiong Jiang; Katharine A Whartenby; Peter A Calabresi
Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(7):4563-70.
2007: Monica V Goldberg; Charles H Maris; Edward L Hipkiss; Andrew S Flies; Lijie Zhen; Rubin M Tuder; Joseph Grosso; Timothy J Harris; Derese Getnet; Katharine A Whartenby; Dirk G Brockstedt; Thomas W Dubensky; Lieping Chen; Drew M Pardoll; Charles G Drake
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
Blood 2007;110(1):186-92.
2007: Brenda R Baldwin; Li Li; Kam-Fai Tse; S Small; Michael I Collector; Katharine A Whartenby; Saul J Sharkis; F Racke; David L Huso; Donald Small
Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.
Leukemia 2007;21(4):764-71.
2007: Fan Pan; Luo Sun; David B Kardian; Katharine A Whartenby; Drew M Pardoll; Jun O Liu
Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin.
Nature 2007;445(7126):433-6.
2005: Katharine A Whartenby; Peter A Calabresi; Erin McCadden; Bao Nguyen; David Kardian; Tianhong Wang; Claudio Mosse; Drew M Pardoll; Donald Small
Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(46):16741-6.
2005: Kimberly Noonan; William Matsui; paolo serafini; Rebecca Carbley; Gladys Tan; Jahan Khalili; Mark Bonyhadi; Hyam I Levitsky; Katharine A Whartenby; Ivan Borrello
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.
Cancer research 2005;65(5):2026-34.
2004: Scott M Freeman; Katharine A Whartenby
The role of the mitogen-activated protein kinase cellular signaling pathway in tumor cell survival and apoptosis.
Drug news & perspectives 2004;17(4):237-42.
2004: Ephraim J Fuchs; Katharine A Whartenby
Hematopoietic stem cell transplant as a platform for tumor immunotherapy.
Current opinion in molecular therapeutics 2004;6(1):48-53.
2003: Katharine A Whartenby
Antigen specific tumor immuno-therapy with lentivirus transduced hematopoietic stem cells for transplant.
Discovery medicine 2003;3(19):26-7.
2003: Yan Cui; Erin Kelleher; Erin Straley; Ephraim J Fuchs; Kevin Gorski; Hyam I Levitsky; Ivan Borrello; Curt I Civin; Stephen P Schoenberger; Linzhao Cheng; Drew M Pardoll; Katharine A Whartenby
Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
Nature medicine 2003;9(7):952-8.
2003: Peter A Calabresi; Rameeza Allie; Katherine M Mullen; Sung Hae Yun; Robert W Georgantas; Katharine A Whartenby
Kinetics of CCR7 expression differ between primary activation and effector memory states of T(H)1 and T(H)2 cells.
Journal of neuroimmunology 2003;139(1-2):58-65.
2002: Katharine A Whartenby; Erin E Straley; Heeje Kim; Frederick Racke; Tanavde Vivek; Kevin Gorski; Linzhao Cheng; Drew M Pardoll; Curt I Civin
Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation.
Blood 2002;100(9):3147-54.
2002: Peter A Calabresi; Sung Hae Yun; Rameeza Allie; Katharine A Whartenby
Chemokine receptor expression on MBP-reactive T cells: CXCR6 is a marker of IFNgamma-producing effector cells.
Journal of neuroimmunology 2002;127(1-2):96-105.
2002: Peter A Calabresi; J L Wilterdink; Jeffrey M Rogg; P Mills; A Webb; Katharine A Whartenby
An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS.
Neurology 2002;58(2):314-7.
2002: Katharine A Whartenby; James W Darnowski; Scott M Freeman; Paul Calabresi
A role for MAP kinase in the antitumor activity of a nucleoside analog.
Cancer gene therapy 2002;9(1):37-43.
2002: Heeje Kim; Katharine A Whartenby; Robert W Georgantas; John Wingard; Curt I Civin
Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis.
Stem cells (Dayton, Ohio) 2002;20(2):174-82.
1999: Katharine A Whartenby; James W Darnowski; Scott M Freeman; K Yurasha; Paul Calabresi
Recombinant interferon alpha2a synergistically enhances ganciclovir-mediated tumor cell killing in the herpes simplex virus thymidine kinase system.
Cancer gene therapy 1999;6(5):402-8.
1998: MY Chu; MH Lipsky; LK Yee; J Epstein; Katharine A Whartenby; S Freeman; TM Chen; Edward Chu; E N Forman; P Calabresi
Predictive sensitivity of human cancer cells in vivo using semipermeable polysulfone fibers.
Pharmacology 1998;56(6):318-26.
1996: SM Freeman; Katharine A Whartenby; J L Freeman; Camille N Abboud; AJ Marrogi
In situ use of suicide genes for cancer therapy.
Seminars in oncology 1996;23(1):31-45.
1995: Katharine A Whartenby; AJ Marrogi; SM Freeman
Gene therapy. Clinical potential and relationship to drug treatment.
Drugs 1995;50(6):951-8.
1995: Katharine A Whartenby; G N Abraham; Peter A Calabresi; Camille N Abboud; P Calabresi; AJ Marrogi; SM Freeman
Gene-modified cells for the treatment of cancer.
Pharmacology & therapeutics 1995;66(1):175-90.
1995: Katharine A Whartenby; Camille N Abboud; AJ Marrogi; R Ramesh; SM Freeman
The biology of cancer gene therapy.
Laboratory investigation; a journal of technical methods and pathology 1995;72(2):131-45.
1993: SM Freeman; Camille N Abboud; Katharine A Whartenby; CH Packman; D S Koeplin; F L Moolten; G N Abraham
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.
Cancer research 1993;53(21):5274-83.
1993: Katharine A Whartenby; R A Insel; SM Freeman; P Keng; G N Abraham
Oncogene elements within an endogenous retrovirus.
Acta virologica 1993;37(2-3):113-22.